JPRN-UMIN000016208招募中未知
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy+duodenojejunostoy for morbid obese patients with diabetes mellitus - A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy+duodenojejunostoy for morbid obese patients with diabetes mellitus
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1, Patiens mental disorders are clearly involved in morbid obesity Background 2, Secondary obesity associated with endocrine disorders 3, Patients determined not to be expected the effect of weight loss surgery 4, Patients with severe renal dysfunction 5, Patients with severe liver failure 6, Pregnant women or women who may possibly be pregnant 7, Patients determined to be inappropriate as a test subject by investigators
研究者
相似试验
尚未招募
2 期
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy with duodenojejunal bypass for obesity with diabetes mellitusMorbid obesity with diabetes mellitusJPRN-UMIN000035537Kansai Medical University Hospital33
招募中
不适用
A phase 2 study to evaluate safety and efficacy of laparoscopic sleeve gastrectomy+duodenojejunostoy for morbid obese patients with diabetes mellitus (Advanced medical care A)Morbid obese patients with diabetes mellitusJPRN-UMIN000030837Tohoku University Hospital10
进行中（未招募）
1 期
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002184-97-FRCentre François Baclesse57
招募中
2 期
uPBSCT with PTCY for ATadult T-cell leukemia/lymphomaJPRN-jRCTs031200375Fukuda Takahiro24
招募中
不适用
Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomasJPRN-UMIN000011152B-SRIM Study Group38